Genotypic classification of patients with Wolfram syndrome: insights into the natural history of the disease and correlation with phenotype by López de Heredia, Miguel et al.
1© American College of Medical Genetics and Genomics SyStematic Review
Wolfram syndrome (WS; OMIM 222300) is a rare, autosomal 
recessive, neurodegenerative, and progressive disease.1–3 Its 
prevalence is estimated to be 1 case per 700,000 people in the 
United Kingdom.4
The minimal ascertainment criterion for diagnosing WS is 
the coincidence of early onset type 1 diabetes mellitus (DM) 
(usually during the first decade of life) and bilateral optic atro-
phy (OA) before the second decade.5 Although these are the 
two basic symptoms, ~50% patients with WS harbor the full 
“DIDMOAD” phenotype—the acronym for diabetes insipi-
dus (DI), DM, OA, and deafness (D).6 Because WS is a pro-
gressive disease, patients generally develop a wide spectrum of 
illnesses during their life, such as psychiatric disorders, renal 
tract abnormalities, nystagmus, ataxia, and loss of deglutition 
reflex, as well as many others.2,4,7–9 Life span is calculated to be 
30–40 years,4 and death usually occurs by respiratory failure 
due to respiratory center atrophy or asphyxia by food aspira-
tion. Several years ago, a particular phenotype was described in 
some Jordanian families in which patients underwent bleeding 
gastrointestinal ulceration and lacked DI.8,9
The gene mutated in almost all patients with WS, WFS1, was 
found and characterized in 1998;10 and mutations in a second 
gene, CISD2, have been described in those Jordanian patients 
with gastrointestinal ulceration.11 WFS1 has also been associ-
ated with an autosomal dominant form of low-frequency sen-
sorineural hearing loss,12–14 autosomal dominant OA,14–16 type 2 
diabetes,17–19 and psychiatric problems.9,15,20
WFS1 has eight exons; the first one is noncoding and com-
prises 33.4 kbp on chromosome 4p16.1.10 Despite being ubiq-
uitously expressed, differences between tissues with high (i.e., 
pancreatic β-cells and brain) and with low (i.e., whole blood 
or kidney) expression are quite significant.10 WFS1 encodes an 
890-amino-acid protein called wolframin, a protein with nine 
transmembrane segments across the endoplasmic reticulum 
membrane (ER)10 and an Ncytoplasm/CER lumen membrane topol-
ogy,21,22 which forms homomeric complexes of 400 kDa under 
physiological conditions.22
Mutations in WFS1 are deleterious for protein expression.23,24 
WFS1 depletion in cells induces high levels of endoplasmic 
reticulum membrane stress, activating the unfolded protein 
response,25,26 and affects insulin processing and secretion.27,28 
Glycosylation sites were identified as important for protein sta-
bility,22 and a region that targets unfolded WFS1 to degradation 
(degron) has been identified.24
The efforts for determining WS natural history have shown 
the order of onset of the different clinical symptoms.29,30 
Nevertheless, the molecular complexity of WS, the wide spec-
trum of associated diseases, and the small size of patient cohorts 
(30–60 patients) complicate the establishment of reliable geno-
type–phenotype correlations. In all attempts, certain WFS1 
mutations were associated with milder or with more severe 
phenotypes.31,32 The data are generally consistent with respect 
to single cohorts of patients, but some contradictions appear 
in comparisons of results from different cohorts. Cano et al.33 
Wolfram syndrome is a degenerative, recessive rare disease with onset 
in childhood. It is caused by mutations in WFS1 or CISD2 genes. 
More than 200 different variations in WFS1 have been described in 
patients with Wolfram syndrome, and no common mutation has been 
determined. This complicates the establishment of a clear genotype–
phenotype correlation. This study analyzed the data of 412 patients 
with Wolfram syndrome published in the past 15 years to further elu-
cidate the role of WFS1 mutations and to update the natural history 
of the disease. Results indicate that (i) 15% of published patients do 
not fulfill the current inclusion criterion, and therefore a new one 
is proposed; (ii) genotypic prevalence differences may exist among 
countries; (iii) the first two clinical features of the syndrome might 
not be diabetes mellitus and optic atrophy; (iv) identified mutations 
distribute nonuniformly on the protein; (v) the age at onset of dia-
betes mellitus, hearing defects, and diabetes insipidus may depend 
on the patient’s genotypic class; and (vi) a progression rate for the 
disease could be estimated that might depend on genotypic class. The 
derived conclusions could be important for patient management and 
counseling as well as for the development of treatments for Wolfram 
syndrome.
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determined that the presence of two inactivating mutations 
that predispose to an earlier onset of DM and OA. Chaussenot 
et al.30 showed no association between the effect of the geno-
type in the neurological signs observed in patients with WS. 
Rohayem et al.34 showed that the age at onset of DM in patients 
carrying predicted complete loss of function mutations is lower 
than those carrying predicted partial or minor loss of function 
mutations.
In this study, by analyzing and comparing WFS1 mutations 
and phenotypes of almost 400 published patients with WS, we 
update the information on the natural history of WS; correlate 
more clinical features with WFS1 mutations on the basis of a 
new classification that considers the putative effect of mutations 
in the protein expression; and estimate, for the first time, the 
progression rate of the syndrome.
MATERIALS AND METHODS
Patients
Clinical and genetic data from 412 patients with WS were 
extracted from 49 references published since 1998 as provided 
by the authors. All patients were described as having WS. When 
possible, patients described in more than one publication were 
identified and their clinical and genetic data were merged into 
a single record. Only 392 patients were used for the analysis 
as either age at onset or diagnosis is provided for at least one 
clinical feature. In all cases, onset and diagnostic age were taken 
to be equivalent. No information was obtained from patients’ 
ancestors because it was mainly not mentioned in the publi-
cations screened. A list of the references used is provided in 
Supplementary Table S1 online.
The variations (mutations and polymorphisms) described 
in the publications have been manually curated, assigned 
an approved Human Genome Variation Society (HGVS) 
nomenclature,35 and compared with those listed in the LOVD-
WFS1 database.36 We analyzed mutations (i) c.2020G→A 
(p.Gly674Arg), considered either a mutation37 or a poly-
morphism,38 and (ii) c.1367G→A (p.Arg456His), considered 
either a mutation34 or a polymorphism,31–33,39,40 because both 
are predicted to produce deleterious proteins by Condel41 and 
PolyPhen-2.42 c.2020G→A is also considered a mutation in the 
LOVD-WFS1 database.
We considered as polymorphisms c.*47C→T33,43,44 and 
c.*253G→A37 because they locate to the 3′-untranslated region 
of WFS1 mRNA, and c.316-37C→T because its effects on 
splicing have not been indicated.34 Supplementary Table S2 
online lists all the mutations described in the patients.
Genotype classification
Mutations were assigned to one of the following types on the 
basis of their predicted effect on WFS1 expression: (i) type I, 
which lead to complete depletion of WFS1 protein due to the 
activation of nonsense-mediated decay,45 including nonsense 
and frameshift mutations producing stop codons before exon 
8 (p.Lys287); (ii) type II, which lead to complete degradation 
of WFS1 protein by keeping functional the degron in WFS1,24 
including all missense mutations except those between amino 
acids 671–700 and those nonsense mutations producing a stop 
codon after p.Trp700; and (iii) type III, leading to the expres-
sion of a defective or shorter WFS1 protein, including nonsense 
mutations that introduce a stop codon after exon 8 and before 
p.Trp700, frameshift mutations introducing a stop codon after 
exon 8, and missense mutations in amino acids 671–700.
Three main genotypic classes were defined: class A, no WFS1 
protein produced; class B, reduced expression of a defective 
WFS1 protein; and, class C, expression of a defective WFS1 pro-
tein. In addition, we subdivided class A into three subclasses: 
class A1, WFS1 depletion due to WFS1 mRNA degradation; 
class A2, WFS1 depletion due to mRNA and protein degrada-
tion; and class A3, WFS1 depletion due to WFS1 protein degra-
dation. Patients were assigned to a genotypic class on the basis of 
mutation types as indicated in Supplementary Table S3 online.
Data processing and statistical analysis
All symptoms described in the publications were pooled and 
categorized into the following clinical features: DM, OA, hearing 
defects (HD), DI, renal or urological problems (UD), and neu-
rological, psychiatric, or developmental problems (ND). If age 
was provided for more than one symptom that fit into the same 
clinical feature, the minimum age was taken as the age at onset.
A life-table approach46 was used for calculating the probabil-
ity of developing each clinical feature, and the probability of 
survival was calculated by a Kaplan–Meier approach. Both are 
available in Supplementary Table S4 online.
The mutation distribution was calculated using a sliding-win-
dow strategy. In brief, the amino acids that harbor mutations in 
a 10-amino-acid window were counted along the protein with 
a 1-amino-acid step. A total of 881 windows were analyzed and 
plotted.
Linear regression methods47 were used to calculate the pro-
gression rate of the syndrome, in years, as follows: the clinical 
features of each of the patients, presenting three or more, were 
ordered by the age at onset and then assigned an ascending 
number starting at 1. The rate of change in age for each of the 
patients was the slope of the linear regression between the fea-
ture order (x-axis) and the age at onset (y-axis). Median and 
SEM for each condition were calculated.
Based on the linear regression analysis, the formula for cal-
culating an expected onset age is Agen = slope (n – 1) + Agen = 1, 
where n is the number of clinical features. The onset age of the 
first feature is taken from the population statistics and corre-
sponds to the median age of the patients within that classifica-
tion for the first clinical feature.
Data were processed with Microsoft Access and Excel 2007 
(Microsoft, Redmond, WA); statistical analysis and some 
graphical representations were done using R48 or SPSS version 
12 (SPSS, Chicago, IL). Random-effects analysis of variance 
methods were used to assess genotypic class–phenotype corre-
lation. Kruskal–Wallis49 analysis of variance was used to assess 
differences in ages of patients across genotype– phenotype. 
Significance level was set at 5%.
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RESULTS
Wolfram syndrome natural history
To update the natural history of WS, the clinical data of 412 
patients with WS published since 1998 were analyzed. Only 
patients with WS confirmed in the publications were consid-
ered for the analysis. From the 392 patients with age specified 
for any clinical symptom, 98.21% had DM; 82.14% OA; 48.21% 
HD; 37.76% DI; 19.39% UD; and 17.09% ND; and 7.40% were 
deceased at the time of publication (see Supplementary Table S5 
online). The population studied presented a median of three 
clinical features, and 59.44% of the patients had developed 1 to 
3 clinical features (see Supplementary Figure S1 online). Onset 
followed this pattern: DM during the first decade of life; OA dur-
ing the early second decade; DI and HD, mainly deafness, dur-
ing the second decade; and UD and ND during the third decade 
(Figure 1a and Supplementary Table S5 online), similar to the 
findings of previous publications.29,30 Although the median age at 
onset of UD (n = 76) was 20 years, a large proportion of patients 
developed UD at 10–20 years of age, and three peaks could be 
observed: one at 13, the second at 21, and the third at 33 years of 
age. Similarly, ND (n = 67) appeared at 10–30 years of age with 
a median of 23 years and two peaks—one at 13, and the other at 
30 years of age. The median age of deceased patients (DE, n = 29) 
was 27 ± 11.4 years, but two peaks of higher frequency could be 
clearly observed—one at 24 and the other at 45 years of age.
The probability of developing each of the clinical features 
was then calculated (Figure 1b and Supplementary Table S4 
online). DM, OA, HD, and DI might have onset during the first 
decade (5% probability at 2–3 years of age for DM, 5–6 for OA, 
7–8 for HD, and 8–9 for DI). The probability of developing DM 
and OA increases sharply during the first two decades (90% 
probability at 14–15 years of age for DM and at 25–26 years for 
OA), then reaches a plateau phase (95% probability at 23–24 
years of age for DM and at 40–41 years for OA). The risk of 
developing HD and DI increases steadily until the third decade 
(at 25–26 years, 60% probability for HD and 50% for DI). From 
this age on, the probability of developing HD rises, up to 92% at 
61–62 years. ND and UD might develop first at the end of the 
first decade or at the beginning of the second decade (5% prob-
ability at 12–13 years of age for UD and 14–15 years for ND). 
Both probabilities steadily increase up to the fifth decade (at 50 
years of age, 53.47% probability of having UD and 64.16% of 
ND). At 18 years of age, the end of the pediatric age, the prob-
ability of having developed the clinical features is: DM, 93.60%; 
OA, 79.06%; HD, 40.56%; DI, 35.20%; UD, 11.42%; and ND, 
7.57%. Life expectancy for patients with WS (Figure 1c and 
Supplementary Table S4 online) decreases slowly up to the 
fifth decade (80.51% at 40 years of age), when a sharp decrease 
is observed (44.75% at 50 years of age).
The pattern of onset of the clinical features was not followed 
by all patients (Figure 1d). Patients mainly start with DM, 
although in 20.5%, this was not the first clinical feature. 57.76% 
mainly developed OA as the second clinical symptom. 41.80% 
mainly developed HD as the third clinical symptom, although 
a large number of patients showed it as fourth or fifth clinical 
manifestation (29.01% and 19.40%, respectively). 35.81% pre-
sented DI as the fourth clinical feature, although 33.11% showed 
it as the third manifestation. UD presented as the fourth or fifth 
clinical symptom by 27.63% or 28.95%, respectively. ND were 
detected as the third, fourth, and fifth clinical feature in 20.90, 
25.37, and 19.40% of the patients, respectively.
When considering the whole set (392 patients), only 110 
(28.06%) showed the full DIDMOAD phenotype. Because the 
median number of clinical features was three, we considered 
the possibility that many patients might still not be old enough 
to develop all four symptoms at the time of publication. Among 
those patients with four or more clinical features, 66.26% ful-
filled the full DIDMOAD phenotype.
We also analyzed whether the current ascertainment crite-
rion, the juvenile onset of DM and OA, was good enough to 
detect all patients with WS (see Supplementary Figure S2 
online). Considering juvenile onset to be onset at ≤18 years of 
age (the upper limit of pediatric age is 18 years in 15 European 
Union countries50) only 85.13% (269 of 316) of the patients had 
both DM and OA.
Genotype distribution
A total of 178 different mutations in WFS1 have been listed in 
this study in 337 of the 412 patients. This means that 18.20% 
of patients had either no access to genetic diagnostic tests, 
no mutations had been identified, or the genetic data were 
not available at the time of publication. Identification of both 
mutated alleles was not possible in all cases. Only one mutation 
was found in WFS1 in 8.31% (28 of 337 patients with described 
genotype). Four of the mutations present in these patients with 
WS have also been associated with dominant diseases such 
as autosomal dominant OA and low-frequency sensorineural 
hearing loss (see Supplementary Table S6 online).
The 178 mutations are distributed nonuniformly all along 
the protein, with no major hotspots (Figure 2a,b). They con-
centrate mainly in transmembrane domains, a region impor-
tant for degradation24 and glycosylation sites. Unexpectedly, 
some mutations concentrate in two additional regions: (i) 
at the n-end of the protein comprising amino acids 94–237 
and (ii) in the last 100 amino acids (Figure 2b), suggesting 
that these regions might be important for protein function, 
although deeper and dedicated research would be needed to 
confirm this point. No founder mutation has been identified, 
and only six mutations were present in >5% of the patients: 
c.2649delC (p.Phe884Serfs*68) in 7.42%; c.1230_1233del 
(p.Val412Serfs*29) in 6.82%; c.409_424dup (p.Val142Glyfs*110) 
in 6.53%; c.2119G→A (p.Val707Ile) in 6.23%; c.1362_1377del 
(p.Tyr454*) in 5.64%; and c.1243_1245del (p.Val415del) in 
5.34% (see Supplementary Table S2 online).
This high heterogeneity complicates setting up a genotype–
phenotype correlation for WS. Therefore, we classified these 
178 mutations into three mutation types on the basis of the 
predicted effect they might have on WFS1 protein expression 
(indicated in the Materials and Methods section). According 
to this classification, we assigned 5.62% of patient mutations 
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to type I, 55.61% to type II, and 38.20% to type III. A small 
number of mutations (0.56%) could not be classified into any 
mutation type because their effect on the protein could not be 
predicted (see Supplementary Table S2 online).
To study whether different mutation types have a role on the 
earlier onset of the clinical features, we classified the patients into 
genotypic classes and subclasses as indicated in the Materials 
and Methods section. The 337 patients were mainly classified 
as class A (51.9%), especially class A3, which represents 42.1% 
(Figure 3a). A total of 7.4% were classified as class A1 and 2.4% 
as class A2. Class B represented 19% and class C, 29.1% of the 
patients. The distribution of the genotypic classes clearly differed 
among countries (Figure 3b and see Supplementary Table S7 
online). Patients in France, Germany, and the United Kingdom 
represented all different genotypic classes, whereas patients in 
Lebanon, Denmark, and Australia were grouped mainly in sub-
class A3, patients from Italy mainly in class C, and those from 
Spain mainly in subclasses A1 and A3. Countries could also be 
classified into two groups: those in which patients with WS were 
mostly classified into genotypic classes in which no WFS1 pro-
tein is produced (Australia, Denmark, France, Iran, Lebanon, 
Spain, and the United Kingdom), and those in which a large pro-
portion of patients, >20%, were classified into genotypic class C 
(Brazil, Germany, Italy, the Netherlands, and Poland).
Genotypic class–phenotype correlation
Comparison of the ages at onset for each genotypic class revealed 
significant differences for DM (P = 0.001) and DI (P = 0.029) 
Figure 1 Insights into Wolfram syndrome. (a) Natural history of WS. The proportion of patients (density) for each clinical feature at onset age, measured 
as a nonparametric probability density distribution, is plotted. For descriptive statistics, see Supplementary Table S3 online. (b) Probability of development 
of WS clinical features by age group. The probability of developing each of the clinical features over age, calculated using a life-table analysis, is displayed. 
For extended information, see Supplementary Table S4 online. (c) Kaplan–Meier analysis of WS. A Kaplan–Meier approach has been used for analyzing the 
probability of survival for patients with WS. For extended information, see Supplementary Table S4 online. (d) Order of clinical feature onset in WS. The order 
in which each clinical feature appears is shown as the percentage of patients with that clinical feature. DM (n = 385); OA (n = 322); HD (n = 189); DI (n = 148); 
ND (n = 67); UD (n = 72). DE, deceased; DI, diabetes insipidus; DM, diabetes mellitus; HD, hearing defects; ND, neurological, psychiatric, and developmental 
defects; OA, optic atrophy; UD, urological or renal defects; WS, Wolfram syndrome.
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when we group the patients into five genotypic classes (Figure 4 
and see Supplementary Table S8 online), and for DI (P = 0.019) 
and HD (P = 0.038) when grouped them into three genotypic 
classes (see Supplementary Figure S3a and Supplementary 
Table S8 online, respectively). A correlation, although not sig-
nificant, for HD (P = 0.099) when grouped into five genotypic 
classes and DM (P = 0.072) when grouped into three genotypic 
classes was also observed. Patients in genotypic class C showed 
earlier onset of most clinical features; in contrast, patients in 
genotypic class A1 presented earlier onset of DM, and patients 
in class A2 developed earlier DI and OA (see Supplementary 
Table S8 online).
Of note, the genotypic classification of UD and ND, and 
the deceased patients showed clearly differentiated groups 
that reflected the bimodal frequencies observed in these clini-
cal symptoms in Figure 1a. In this sense, patients classified as 
Figure 2 Mutations distribution in WFS1. (a) Mutation position. Position and type of each mutation is shown in a schematic model of WFS1 protein. The 
position of the degron (amino acids 671–700),24 the first amino acid encoded by exon 8 (p.Lys287), the two glycosylation sites,22 and the amino acid positions 
at ER membrane contacts are indicated. Amino acid positions can have more than one mutation and have a different color only if affected by different mutation 
types. Color code identifies mutation types at that amino acid position: blue, type I mutation; red, type II; green, type III; cyan, type II or III; yellow, type I 
or II. (b) Mutation distribution. The number of mutations is calculated for a 10-amino-acid sliding window along the protein. White boxes below the chart 
indicate windows including the transmembrane domains; blue box indicates windows including the degron.24 Glycosylation sites22 are also indicated at their 
approximated locations. ER, endoplasmic reticulum.
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Figure 3 Genotypic class distribution in patients with Wolfram syndrome. (a) Genotypic class distribution in the whole population. The percentage of 
patients with each genotypic class and subclass is represented. n = 337. (b) Genotypic class distribution among countries. The number of patients classified into 
each genotypic class and subclass in some of the countries (those with more than six patients) is presented. For an extension of the data, see Supplementary 
Table S5 online.
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class A2 have an onset of UD at 30 years of age, whereas those 
classified as class C have onset at 15 years (Figure 4), correlat-
ing with the two peaks observed in patient frequency for this 
clinical feature (Figure 1a). Furthermore, patients classified as 
class A1 have an onset of ND at 30 years of age, and in those 
in class B or C the onset was at the end of the second decade 
(Figure  4), which correlates with the two peaks observed in 
patient frequency (Figure 1a). Deceased patients were distrib-
uted in two clearly differentiated groups: patients with class A1, 
with a median age at onset of 40 years, and those with class 
C, with a median of 25 years of age (Figure 4), similar to the 
two peaks observed in patient frequency (Figure 1a). No differ-
ences between sexes were detected (data not shown).
To compare among different genotyping methods, we also 
correlated genotype and phenotype using other previously 
described genotypic classifications with this data set (see 
Supplementary Figure S3b,c and Supplementary Table  S8 
online). The genotyping methods of Cano et al.33 and Chaussenot 
et al.30 were based on mutation types and differ from each other 
only in genotype naming. The genotyping method of Rohayem 
et al.34 was based on the effect of mutations on the function of 
WFS1. In the analysis performed, a significant correlation was 
found only for DM and OA with both methodologies, similar 
to the findings in the original publications of Cano et al.33 and 
Chaussenot et al.30 and expanding the findings in Rohayem 
et al.34 By contrast, a significant correlation for DI and HD 
(see Supplementary Figures S3a and Supplementary Table 
S8 online) was observed when grouped into three genotypic 
classes and for DM and DI when grouped into five genotypic 
classes (Figure 4 and see Supplementary Table S8 online) with 
the approach described here.
Clinical progression of Wolfram syndrome
Although there is indisputable interest in knowing whether 
the evolution of the disease depends on the different genetic 
backgrounds, the evolution rate of patients with WS through 
the different clinical features is still unknown. We therefore 
used a regression approach, as indicated in the Materials and 
Methods section, on those patients harboring three or more 
clinical features, as a way to estimate the evolution rate of WS in 
the general population (Figure 5, shadowed line). We obtained 
a progression rate of 3.90 ± 0.222 (n = 260) for the whole set of 
patients analyzed, indicating how fast patients with WS develop 
the clinical features. We then estimated the rate for the differ-
ent genotypic classes. If the estimated rate is smaller than that 
of the general population, it would mean that the onset of the 
different clinical features is earlier, and, therefore, the overall 
phenotype might be worse as more manifestations of the dis-
ease have started. When the genotypic classification previously 
defined was considered for the estimation of the rate (Figure 5 
and Supplementary Table S9 online), the progression rate of 
the disease through the clinical features was significantly faster 
in patients in genotypic class C (3.50 ± 0.261, n = 69), and 
faster for classes-A2 (2.90 ± 1.443, n = 7) and B (3.60 ± 0.592, 
n = 48) than the general population. Those in genotypic class 
A1 (4.90 ± 0.796, n = 21) showed a slower progression rate 
than the population of patients with WS in genotypic class A3 
(4.0 ± 0.376, n = 112).
DISCUSSION
The data published over the past 15 years allowed us to carry 
out a deep study on the onset of the clinical features and to 
describe how patients with WS evolved thanks to the large 
number of patients described. The approach used has its pit-
falls due to differences between publications in (i) the amount 
of data reported, (ii) the age when the different clinical analysis 
are done, (iii) the clinical threshold for presenting the differ-
ent symptoms, and (iv) the accuracy of the onset ages of some 
clinical features due to unrecognized subtle changes (i.e., ND) 
or different clinical thresholds (i.e., UD), among other reasons. 
Getting a well-characterized cohort that is managed under 
standardized criteria and large enough to allow the analysis 
presented here with high-quality data will not be possible until 
further population and integration of the disease-associated 
registers recently initiated in the United States, Europe, and 
Spain, due to the low prevalence of WS.
The picture of the natural history of the disease obtained 
here is in agreement with the ones previously published29,30 and 
extend the knowledge. The main differences observed are in the 
onset of UD and ND, although detailed age of onset was only 
provided for a limited number of patients (76 of 148 with UD 
and 67 of 141 with ND), complicating an accurate analysis. In 
the set of patients used here, the median age at onset for UD was 
20 years (n = 76), similar to Barrett’s series (n = 30) and differ-
ent from the 12 years in Chaussenot’s series (n = 59). The peaks 
detected on the frequency of patients with UD (Figure 1a) cor-
related with the median onset age in genotypic class A1 or C for 
[Q13]
Figure 5 Progression rate of Wolfram syndrome. The progression rate of 
patients with Wolfram syndrome with three or more clinical features sorted 
by the age of onset is calculated as the slope of the linear regression that 
binds them. Median ± SEM is shown for each genotypic class inside the 
histograms. The slope was calculated from 21 patients in class A1; 7 in class 
A2; 133 in class A3; 49 in class B; and 70 in class C. The median slope ± 
SEM for all the patients (n = 260) is shown as a dashed line and gray area, 
respectively. Slopes that are higher than the population median show slower 
progression rates than the general population, and those that are smaller 
show faster progression rates. *P = 0.009.
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the first (13 years), class B for the second (21 years), and A2 for 
the third peak (33 years, Figure 4).
Similarly, the onset of ND also differs with previous data. In 
Chaussenot’s series, the onset was 15 years of age (n = 30),30 half 
the age of Barrett’s series (n = 12).29 In the set of patients used 
here the two peaks detected, one at 13 and the other at 30 years 
of age (Figure 1a), correlated with the median age of class A1 
for the first peak and class B or C for the second one (Figure 4). 
These results together suggest that different genotypic classes 
could be behind these differences in the frequency distribution 
of the clinical features. More detailed phenotype information is 
therefore needed for refining these observations.
Among all patients analyzed, 66.26% had the full DIDMOAD 
phenotype when considering only those with four or more 
symptoms. This number is higher than the one previously 
reported,6 and indicates that one-third of patients with WS 
might not show the four classical clinical features defining the 
syndrome.
The current ascertainment criterion for WS is the juvenile 
onset of DM and OA. Considering juvenile onset as equiva-
lent to age 18,50 almost 15% of the patients in the present series 
who had both clinical features did not fulfill this criterion (see 
Supplementary Figure S2 online), indicating that people 
affected by this disease might be underestimated. Furthermore, 
the calculated probability of developing each of the clinical fea-
tures at 18 years of age for DM and OA is not 100% (Figure 1b 
and Supplementary Table S4 online). We suggest changing 
this criterion. To this end, we foresee two possibilities: (i) to 
consider patients with DM and OA at any age. In this situation, 
96.05% of the patients would be included (316 of 329 patients 
with two or more clinical features); or (ii) to take patients with 
two of any of the DIDMOAD symptoms. Then, 98.78% of the 
patients would be included (325 of 329 patients with two or 
more clinical features). We propose the latter criterion to be 
used for considering WS because it may help to genetically 
diagnose almost all patients with WS earlier and might allow 
detection of atypical WS patients.15,16,51 Furthermore, 20% of 
patients with WS do not debut with DM but other clinical fea-
tures, and a large proportion do not develop as a second clinical 
feature DM or OA (Figure 1d). All these data together suggest 
a wider heterogeneity in WS than previously demonstrated by 
other studies and has important implications in the clinical spe-
cialties that have to be aware of this disease.
Based on predicting the effect of WFS1 mutations on protein 
expression using current knowledge on cell functioning and in 
WFS1 protein stability, we have classified the mutations into 
three different types. Type I mutations are those that activate the 
mechanism used by the cell to degrade aberrant mRNAs (non-
sense-mediated decay), leading to the absence of wolframin due 
to mRNA degradation. Although it has not been demonstrated 
in patients with WS, those mutations that lead to the creation 
of a premature stop codon before the beginning of the last exon 
(exon 8 in WFS1) are at risk for activating this mechanism.45,52
We have classified remaining mutations into type II or III, 
based on the recent finding of a sequence that targets unfolded 
WFS1 to degradation (degron) between amino acids 671 and 
700.24 Differences in protein stability have already been dem-
onstrated for some previously published WFS1 mutations. 
Heterologous expression in human cells of WFS1 mutants that 
keep this degron (type II mutations), such as p.Pro504Leu, 
p.Arg629Trp, p.Trp700*, p.Pro704Leu, p.Pro724Leu, 
p.Glu737Lys, p.Phe883*, and p.Pro885Leu, led to cellular deple-
tion or reduced expression of WFS1 protein.23,24 By contrast, the 
expression of mutants that affect this region (type III mutants), 
such as p.Trp648*, p.Tyr660*, and p.Gln667*, was similar to the 
expression of the wild-type protein.23,24
Furthermore, WFS1 expression in previously published 
patients supports the mutation and genotypic classifications we 
propose. In this sense, a patient predicted to be classified into 
genotypic class B for carrying heterozygous type II and type III 
mutations (p.Arg629Trp and p.Trp371*, respectively) showed 
a reduced content of a defective WFS1 protein. Furthermore, 
a patient classified genotypically into class A3 (homozygous 
for p.Trp700*, a type II mutation) showed no WFS1 protein 
expressed,23 in concordance also with the heterologous expres-
sion of this mutant. In addition, as predicted, a patient homo-
zygous for a type II mutation, c.2452C→T (p.Arg818Cys), and 
classified into class A3, showed no WFS1 protein expressed (see 
Supplementary Figure S4 online).
The lack of one mutant allele in 8.31% of the patients points 
to: (i) the lack of detection of a second mutation, (ii) the exis-
tence of dominant mutations, or (iii) mutations in another gene. 
Because no data are available on any MLPA analysis performed 
on these patients, the presence of deleted WFS1 regions is possi-
ble. In addition, the effect on WFS1 expression of those variations 
located in the promoter or 5′- or 3′-untranslated regions of WFS1 
mRNA and the effect on WFS1 localization and activity of many 
variations are still unknown. We could then envision that new 
classes and subclasses based on WFS1 protein localization, activ-
ity, or expression might need to be defined. A functional assay 
allowing further and intensive research in the effect of WFS1 
variations is needed for properly classifying all variations.
The genotypic class–phenotype correlation performed indi-
cates that the differences observed in the age at onset of DM, DI, 
and HD correlates with the genotypic classification performed. 
We could not exclude a role in the other clinical features ana-
lyzed (UD, ND, and deceased); additional patients with these 
features should be evaluated. For comparison purposes, we also 
performed the genotype–phenotype correlation using other 
described genotypic classifications30,33,34 with the same data set. 
In the analysis performed, a significant correlation was found 
only for DM and OA with all methodologies tested, similar to 
the findings in the original publications of Cano et al.33 and 
Chaussenot et al.30 and expanding the findings of Rohayem et al.34 
By contrast, we observed significant correlations in DM, DI, and 
HD with our genotyping strategy (Figure 3 and Supplementary 
Figure S4 and Supplementary Table S8 online). All this sug-
gests that the depletion or expression of a mutated form of 
WFS1 might play a role in determining the age at onset of these 
clinical features in patients with WS.
[Q14]
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It was possible, for the first time, to estimate the rate at which 
the patients developed the different clinical features in WS. 
Of note, this progression rate varied in accordance with the 
patient’s genotypic class, providing the first clues that might 
explain the differences in the development of the phenotype 
between patients. Furthermore, the calculation of age at onset 
of the clinical manifestations based on this estimation and the 
genotypic classification gets very close to the observed median 
for that genotype (see Supplementary Table S9 online). These 
data support our genotyping approach and progression-rate 
estimation, although the accuracy and predictive value of the 
progression rate would be highly improved if the amount of 
data and the comparative quality of data were increased.
Because WS is a rare disease, it is difficult to study patient 
cohorts that are large enough without the cooperation of 
researchers from different countries. This means that nor-
malized, detailed, and high-quality phenotypic and genotypic 
information should be recorded for all patients. The initiatives 
from the European53 and Spanish registers (EURO-WABB 
(http://www.euro-wabb.org) and REWBA (https://rewba.idi-
bell.cat), respectively) could provide, in the near future, the 
data to address these and other unsolved questions. Definitive 
knowledge about the natural history of WS will come from 
the integration of the data in the aforementioned registers and 
those from other countries, such as the one in the United States 
(https://wolframsyndrome.dom.wustl.edu/medical-research/
Wolfram-Syndrome-Home.aspx), into an international regis-
ter. The results presented in here, although based on question-
able quality of data, provide the deepest view of the natural his-
tory of WS obtained with currently available data.
WS is a monogenic disease, and its characteristics could make 
it a useful model for understanding more complex diseases such 
as DM, OA, HD, and other neurologically related clinical symp-
toms. The genotypic classification of patients helps to develop 
an understanding of the observed differences between patients.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper 
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